BIBLIOGRAFIA
Alke, A., A. Schwantes, K. Kido, M. Flotenmeyer, R.M. Flugel, and M. Lochelt. 2001. The bet gene of feline foamy virus is required for virus replication.
Virology. 287:310-20.
Alke, A., A. Schwantes, M. Zemba, R.M. Flugel, and M. Lochelt. 2000. Characterization of the humoral immune response and virus replication in cats experimentally infected with feline foamy virus. Virology. 275:170-6. Amara, R.R., F. Villinger, J.D. Altman, S.L. Lydy, S.P. O'Neil, S.I. Staprans, D.C.
Montefiori, Y. Xu, J.G. Herndon, L.S. Wyatt, M.A. Candido, N.L. Kozyr, P.L. Earl, J.M. Smith, H.L. Ma, B.D. Grimm, M.L. Hulsey, J. Miller, H.M. McClure, J.M. McNicholl, B. Moss, and H.L. Robinson. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science. 292:69-74.
Baldwin, D.N., and M.L. Linial. 1998. The roles of Pol and Env in the assembly pathway of human foamy virus. J Virol. 72:3658-65.
Bar, S., and M. Alizon. 2004. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. J Virol. 78:811-20.
Bendinelli, M., M. Pistello, S. Lombardi, A. Poli, C. Garzelli, D. Matteucci, L. Ceccherini-Nelli, G. Malvaldi, and F. Tozzini. 1995. Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev. 8:87-112.
Blomer, U., L. Naldini, T. Kafri, D. Trono, I.M. Verma, and F.H. Gage. 1997. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol. 71:6641-9.
Bodem, J., M. Lochelt, P. Yang, and R.M. Flugel. 1997. Regulation of gene expression by human foamy virus and potentials of foamy viral vectors.
Carnec, X., L. Quan, W.C. Olson, U. Hazan, and T. Dragic. 2005. Anti-CXCR4 monoclonal antibodies recognizing overlapping epitopes differ significantly in their ability to inhibit entry of human immunodeficiency virus type 1. J
Virol. 79:1930-3.
Chong, H., W. Starkey, and R.G. Vile. 1998. A replication-competent retrovirus arising from a split-function packaging cell line was generated by recombination events between the vector, one of the packaging constructs, and endogenous retroviral sequences. J Virol. 72:2663-70.
Cullen, B.R. 1992. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev. 56:375-94.
Dimitrov, A.S., S.S. Rawat, S. Jiang, and R. Blumenthal. 2003. Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion. Biochemistry. 42:14150-8.
Elyar, J.S., M.C. Tellier, J.M. Soos, and J.K. Yamamoto. 1997. Perspectives on FIV vaccine development. Vaccine. 15:1437-44.
Enssle, J., N. Fischer, A. Moebes, B. Mauer, U. Smola, and A. Rethwilm. 1997. Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle. J Virol. 71:7312-7.
Finzi, D., and R.F. Siliciano. 1998. Viral dynamics in HIV-1 infection. Cell. 93:665-71.
Flynn, J.N., P. Keating, M.J. Hosie, M. Mackett, E.B. Stephens, J.A. Beatty, J.C. Neil, and O. Jarrett. 1996. Env-specific CTL predominate in cats protected from feline immunodeficiency virus infection by vaccination. J Immunol. 157:3658-65.
Giannecchini, S., F. Bonci, M. Pistello, D. Matteucci, O. Sichi, P. Rovero, and M. Bendinelli. 2004. The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. Virology. 320:156-66.
Giannecchini, S., A. Di Fenza, A.M. D'Ursi, D. Matteucci, P. Rovero, and M. Bendinelli. 2003. Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein. J Virol. 77:3724-33.
Giri, M., K.E. Ugen, and D.B. Weiner. 2004. DNA vaccines against human immunodeficiency virus type 1 in the past decade. Clin Microbiol Rev. 17:370-89.
Gurunathan, S., C.Y. Wu, B.L. Freidag, and R.A. Seder. 2000. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol. 12:442-7.
Haddad, D., J. Ramprakash, M. Sedegah, Y. Charoenvit, R. Baumgartner, S. Kumar, S.L. Hoffman, and W.R. Weiss. 2000. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol. 165:3772-81.
Hill, C.L., P.D. Bieniasz, and M.O. McClure. 1999. Properties of human foamy virus relevant to its development as a vector for gene therapy. J Gen Virol. 80 ( Pt 8):2003-9.
Hosie, M.J., T. Dunsford, D. Klein, B.J. Willett, C. Cannon, R. Osborne, J. Macdonald, N. Spibey, N. Mackay, O. Jarrett, and J.C. Neil. 2000. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J Virol. 74:9403-11.
Karlas, J.A., K.H. Siebelink, M.A. Peer, W. Huisman, A.M. Cuisinier, G.F. Rimmelzwaan, and A.D. Osterhaus. 1999. Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection. J Gen Virol. 80 ( Pt 3):761-5.
Korber, B., B. Gaschen, K. Yusim, R. Thakallapally, C. Kesmir, and V. Detours. 2001. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 58:19-42.
Lecellier, C.H., and A. Saib. 2000. Foamy viruses: between retroviruses and pararetroviruses. Virology. 271:1-8.
Leitner, W.W., H. Ying, and N.P. Restifo. 1999. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine. 18:765-77.
Letvin, N.L., Y. Huang, B.K. Chakrabarti, L. Xu, M.S. Seaman, K. Beaudry, B. Korioth-Schmitz, F. Yu, D. Rohne, K.L. Martin, A. Miura, W.P. Kong, Z.Y. Yang, R.S. Gelman, O.G. Golubeva, D.C. Montefiori, J.R. Mascola, and G.J.
Nabel. 2004. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol. 78:7490-7.
Linial, M.L. 1999. Foamy viruses are unconventional retroviruses. J Virol. 73:1747-55.
Lochelt, M. 2003. Foamy virus transactivation and gene expression. Curr Top
Microbiol Immunol. 277:27-61.
Lochelt, M., and R.M. Flugel. 1996. The human foamy virus pol gene is expressed as a Pro-Pol polyprotein and not as a Gag-Pol fusion protein. J Virol. 70:1033-40.
Lochelt, M., W. Muranyi, and R.M. Flugel. 1993. Human foamy virus genome possesses an internal, Bel-1-dependent and functional promoter. Proc Natl
Acad Sci U S A. 90:7317-21.
Lombardi, S., C. Garzelli, M. Pistello, C. Massi, D. Matteucci, F. Baldinotti, G. Cammarota, L. da Prato, P. Bandecchi, F. Tozzini, and et al. 1994. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol. 68:8374-9.
Matteucci, D., M. Pistello, P. Mazzetti, S. Giannecchini, D. Del Mauro, I. Lonetti, L. Zaccaro, C. Pollera, S. Specter, and M. Bendinelli. 1997. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against free and cell-associated challenge differs in duration and is not easily boosted. J Virol. 71:8368-76.
Matteucci, D., A. Poli, P. Mazzetti, S. Sozzi, F. Bonci, P. Isola, L. Zaccaro, S. Giannecchini, M. Calandrella, M. Pistello, S. Specter, and M. Bendinelli. 2000. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J Virol. 74:10911-9.
McCutchan, F.E. 2000. Understanding the genetic diversity of HIV-1. Aids. 14 Suppl 3:S31-44.
McShane, H. 2002. Prime-boost immunization strategies for infectious diseases.
Curr Opin Mol Ther. 4:23-7.
Meiering, C.D., and M.L. Linial. 2002. Reactivation of a complex retrovirus is controlled by a molecular switch and is inhibited by a viral protein. Proc
Miyoshi, H., U. Blomer, M. Takahashi, F.H. Gage, and I.M. Verma. 1998. Development of a self-inactivating lentivirus vector. J Virol. 72:8150-7.
Munoz-Barroso, I., K. Salzwedel, E. Hunter, and R. Blumenthal. 1999. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol. 73:6089-92.
Naldini, L., U. Blomer, F.H. Gage, D. Trono, and I.M. Verma. 1996. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. 93:11382-8.
Nowak, M.A., R.M. May, and K. Sigmund. 1995. Immune responses against multiple epitopes. J Theor Biol. 175:325-53.
Omori, M., R. Pu, T. Tanabe, W. Hou, J.K. Coleman, M. Arai, and J.K. Yamamoto. 2004. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine. Vaccine. 23:386-98.
O'Neill, E., I. Martinez, F. Villinger, M. Rivera, S. Gascot, C. Colon, T. Arana, M. Sidhu, R. Stout, D.C. Montefiori, M. Martinez, A.A. Ansari, Z.R. Israel, and E. Kraiselburd. 2002. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J Med Primatol. 31:217-27.
Pedersen, N.C., E.W. Ho, M.L. Brown, and J.K. Yamamoto. 1987. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science. 235:790-3.
Pietschmann, T., M. Heinkelein, M. Heldmann, H. Zentgraf, A. Rethwilm, and D. Lindemann. 1999. Foamy virus capsids require the cognate envelope protein for particle export. J Virol. 73:2613-21.
Preston, B.D. 1997. Reverse transcriptase fidelity and HIV-1 variation. Science. 275:228-9; author reply 230-1.
Pu, R., J. Coleman, M. Omori, M. Arai, T. Hohdatsu, C. Huang, T. Tanabe, and J.K. Yamamoto. 2001. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.
Aids. 15:1225-37.
Rethwilm, A. 1995. Regulation of foamy virus gene expression. Curr Top Microbiol
Rethwilm, A. 2003. The replication strategy of foamy viruses. Curr Top Microbiol
Immunol. 277:1-26.
Russell, D.W., and A.D. Miller. 1996. Foamy virus vectors. J Virol. 70:217-22. Saib, A. 2003. Non-primate foamy viruses. Curr Top Microbiol Immunol.
277:197-211.
Salzwedel, K., J.T. West, and E. Hunter. 1999. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J Virol. 73:2469-80.
Schwantes, A., U. Truyen, J. Weikel, C. Weiss, and M. Lochelt. 2003. Application of chimeric feline foamy virus-based retroviral vectors for the induction of antiviral immunity in cats. J Virol. 77:7830-42.
Schweizer, M., V. Falcone, J. Gange, R. Turek, and D. Neumann-Haefelin. 1997. Simian foamy virus isolated from an accidentally infected human individual. J Virol. 71:4821-4.
Smith, J.M., and J.V. Torres. 2001. A retroviral DNA vaccine vector. Viral
Immunol. 14:339-48.
Sun, X., L.M. Hodge, H.P. Jones, L. Tabor, and J.W. Simecka. 2002. Co-expression of granulocyte-macrophage colony-stimulating factor with antigen enhances humoral and tumor immunity after DNA vaccination.
Vaccine. 20:1466-74.
Tadokoro, C.E., and I. de Almeida Abrahamsohn. 2001. Bone marrow-derived macrophages grown in GM-CSF or M-CSF differ in their ability to produce IL-12 and to induce IFN-gamma production after stimulation with Trypanosoma cruzi antigens. Immunol Lett. 77:31-8.
Tobaly-Tapiero, J., P. Bittoun, M. Neves, M.C. Guillemin, C.H. Lecellier, F. Puvion-Dutilleul, B. Gicquel, S. Zientara, M.L. Giron, H. de The, and A. Saib. 2000. Isolation and characterization of an equine foamy virus. J Virol. 74:4064-73.
Trono, D. 2003. Virology. Picking the right spot. Science. 300:1670-1.
Uhl, E.W., T.G. Heaton-Jones, R. Pu, and J.K. Yamamoto. 2002. FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review. Vet Immunol Immunopathol. 90:113-32.
Van Tendeloo, V.F., C. Van Broeckhoven, and Z.N. Berneman. 2001. Gene therapy: principles and applications to hematopoietic cells. Leukemia. 15:523-44.
Vassilopoulos, G., N.C. Josephson, and G. Trobridge. 2003. Development of foamy virus vectors. Methods Mol Med. 76:545-64.
Vassilopoulos, G., G. Trobridge, N.C. Josephson, and D.W. Russell. 2001. Gene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors. Blood. 98:604-9.
Wang, G., and M.J. Mulligan. 1999. Comparative sequence analysis and predictions for the envelope glycoproteins of foamy viruses. J Gen Virol. 80 ( Pt 1):245-54.
Warren, T.L., and G.J. Weiner. 2000. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr Opin Hematol. 7:168-73. Winkler, I.G., R.M. Flugel, M. Lochelt, and R.L. Flower. 1998. Detection and
molecular characterisation of feline foamy virus serotypes in naturally infected cats. Virology. 247:144-51.
Winkler, I.G., M. Lochelt, and R.L. Flower. 1999. Epidemiology of feline foamy virus and feline immunodeficiency virus infections in domestic and feral cats: a seroepidemiological study. J Clin Microbiol. 37:2848-51.
Woodland, D.L. 2004. Jump-starting the immune system: prime-boosting comes of age. Trends Immunol. 25:98-104.
Yamamoto, J.K., T. Okuda, C.D. Ackley, H. Louie, E. Pembroke, H. Zochlinski, R.J. Munn, and M.B. Gardner. 1991. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res Hum Retroviruses. 7:911-22.
Yi, Y., F. Shaheen, and R.G. Collman. 2005. Preferential use of CXCR4 by R5X4 human immunodeficiency virus type 1 isolates for infection of primary lymphocytes. J Virol. 79:1480-6.
Zemba, M., T. Wilk, T. Rutten, A. Wagner, R.M. Flugel, and M. Lochelt. 1998. The carboxy-terminal p3Gag domain of the human foamy virus Gag precursor is required for efficient virus infectivity. Virology. 247:7-13.
